Napolitano, Daniele
 Distribuzione geografica
Continente #
NA - Nord America 265
EU - Europa 252
AS - Asia 127
AF - Africa 2
Totale 646
Nazione #
US - Stati Uniti d'America 260
IT - Italia 79
SE - Svezia 67
SG - Singapore 62
CN - Cina 27
IE - Irlanda 23
ID - Indonesia 22
FR - Francia 21
DE - Germania 18
KR - Corea 10
RU - Federazione Russa 9
FI - Finlandia 6
SI - Slovenia 6
CA - Canada 5
GB - Regno Unito 5
PT - Portogallo 4
ES - Italia 2
IN - India 2
JP - Giappone 2
LT - Lituania 2
UA - Ucraina 2
BE - Belgio 1
BG - Bulgaria 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
EE - Estonia 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
MK - Macedonia 1
NG - Nigeria 1
PL - Polonia 1
RO - Romania 1
Totale 646
Città #
Chandler 70
Singapore 53
Ashburn 33
New York 29
Rome 25
Dublin 21
Jakarta 21
Milan 13
Marseille 12
Boardman 11
Seoul 10
Beijing 8
Los Angeles 8
Moscow 7
Princeton 7
Munich 6
Boston 5
Helsinki 5
Paris 5
Bremen 4
Atlanta 3
Chelsea 3
Lisbon 3
San Diego 3
Washington 3
Ancona 2
Cagliari 2
Dongyang 2
Fairfield 2
Florence 2
Frankfurt am Main 2
Genzano di Roma 2
Houston 2
Logroño 2
Oristano 2
Ottawa 2
Pune 2
Saint-Fons 2
San Mateo 2
Seattle 2
Toronto 2
Abidjan 1
Arzachena 1
Augusta 1
Brno 1
Brussels 1
Busto Arsizio 1
Ceriano Laghetto 1
Gdansk 1
Hackney 1
Hirakata 1
Iesi 1
Lagos 1
Lappeenranta 1
Leawood 1
Massa 1
Montreal 1
Monza 1
Nagoya 1
Nanjing 1
Naples 1
Newark 1
Nuremberg 1
Ravenna 1
Sacramento 1
Santa Clara 1
Tallinn 1
Trieste 1
Wilmington 1
Zagreb 1
Totale 429
Nome #
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 64
Knowledge of Diagnostic and Therapeutic Aspects of IBD Among Nurses Working in Digestive Endoscopy: A Nationwide Italian Survey 59
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 54
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 53
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 51
The awareness of the IBD nurse position among patients from an Italian tertiary IBD centre 50
The role of inflammatory bowel disease nurses for patients on biologic therapy during the COVID-19 pandemic 47
Gut Microbiota Signatures Are Associated With Psychopathological Profiles in Patients With Ulcerative Colitis: Results From an Italian Tertiary IBD Center 36
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 36
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study 28
Knowledge of perianal Crohn's disease among nurses in an Italian tertiary centre 25
Evaluation of factors associated with trust in telemedicine in patients with inflammatory bowel disease during COVID-19 pandemic: a multicenter cross-sectional survey 23
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients 22
The educational role of IBD nurses in Italy in vaccinations: do not miss the moment for COVID-19 21
Serial Fecal Microbiota Infusions via Colonoscopy for Active Ulcerative Colitis: A Feasibility, Safety, and Translational Monocentric Italian Study 19
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study 18
Self-care in patients affected by inflammatory bowel disease and caregiver contribution to self-care (IBD-SELF): a protocol for a longitudinal observational study 18
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy 12
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study 11
Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study 9
Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission 9
Knowledge of perianal Crohn's disease among nurses in an Italian tertiary centre 4
Totale 669
Categoria #
all - tutte 4.654
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.654


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213 0 0 0 0 0 0 0 0 0 0 1 2
2021/202258 1 0 0 2 1 0 0 3 0 18 16 17
2022/2023222 36 28 10 32 18 14 22 7 18 6 15 16
2023/2024251 6 40 16 19 11 35 21 7 17 21 24 34
2024/2025135 8 11 63 22 31 0 0 0 0 0 0 0
Totale 669